Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Alterity Therapeutics (ATH) says it has secured a “broad monopoly” over a class of compounds capable of redistributing excess iron in the central nervous system
  • The patent covers small molecule drug candidates which could be used to target excess iron in patients with Alzheimer’s and Parkinson’s disease
  • It comes as the company gears up for phase two of its lead clinical candidate ATH434, due to take place by the end of the year
  • The patent was issued by the United States Patent and Trademark Office and is granted to Alterity for 20 years
  • Alterity Therapeutics closed today’s session up 7.14 per cent at 3 cents

Alterity Therapeutics (ATH) says it has secured a “broad monopoly” over a class of compounds capable of redistributing excess iron in the central nervous system.

Specifically, the patent covers small molecule drug candidates, which ATH claim has potential to cross the blood-brain barrier and directly attack a source of
neuropathology.

Excess iron in the brain is associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

Following the grant of “Compounds for and Methods of Treating Diseases”, ATH now has rights to more than 150 novel pharmaceutical compositions aimed at redistributing iron in patients with said diseases.

The patent grant comes as the company gears up for the phase two trial of its lead clinical candidate ATH434 — to treat Multiple System Atrophy — due to take place by the end of the year.

Alterity Chief Executive officer Dr David Stamle said the patent represented an important part of its corporate strategy.

“The newly covered compounds target excess brain iron that is increased in these
conditions and we hope to identify a new clinical candidate by the time we get results from our lead clinical program,” he said.

The patent was issued by the United States Patent and Trademark Office and is granted to Alterity for 20 years.

Alterity Therapeutics closed today’s session up 7.14 per cent at 3 cents.

ATH by the numbers
More From The Market Herald
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.

" Paragon Care (ASX:PGC) enters partnership with Centuria Healthcare for a healthcare facility

Paragon Care (PGC) has entered into a partnership with Centuria Healthcare for the 15-year lease of a state-of-the-art healthcare facility in Melbourne.